1. What is NKMAX’s delisting review about?
NKMAX faces a high probability of being subject to a delisting review due to reasons such as accumulated penalties for inaccurate disclosures. On September 3, 2025, the Korea Exchange will decide whether NKMAX will remain listed. If designated for review, the possibility of delisting must be considered.
2. Why is NKMAX under review?
This is due to accumulating 15 or more penalty points for inaccurate disclosures within the past year. This is in accordance with Korea Exchange regulations emphasizing the disclosure obligations of listed companies to protect investors. Stricter criteria apply to companies undergoing rehabilitation proceedings.
3. How will the review results impact the stock price?
- If included in the review: A sharp drop in stock price and prolonged trading suspension are highly likely. Investor sentiment may be severely dampened due to delisting concerns.
- If excluded from the review: Trading resumption and a rebound in stock price can be expected. However, sustained growth is difficult to anticipate without fundamental improvements in the company.
4. What should investors do?
Investors should pay close attention to the results of the delisting review to be announced on September 3rd. Short-term investment carries very high risk. From a mid-to-long-term perspective, careful consideration should be given to the implementation of the rehabilitation plan, synergy effects with the new major shareholder, and the development progress of the immunotherapy pipeline. Hasty investment decisions can lead to significant losses, so a cautious approach is necessary.
Frequently Asked Questions
Will NKMAX be delisted?
This will be determined based on the results of the substantive examination on September 3rd. If designated for review, the likelihood of delisting increases.
Should I buy NKMAX stock now?
Currently, investing in NKMAX carries very high risk. Prudent investment decisions are necessary.
What is the future of NKMAX?
Key factors that will determine the future value of the company include passing the delisting review, successful implementation of the rehabilitation plan, and progress in the development of immunotherapeutic agents.